MarginsXMarginsX
Home › Markets › Health Care › BIOA

BioAge Labs Inc. (BIOA)

BIOA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.22
-5.95% on the day
Market cap
$239.9M
Micro cap
Revenue · 2025
$9.0M
Prior year not contiguous
Net income · 2025
-$80.6M
-896.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/0001193125-26-120873-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBIOA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2024
SEC CIK0001709941
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$9.0M
Net income-$80.6M
Operating income-$92.8M
Net margin-896.1%
Operating margin-1031.5%
Revenue growthNo prior-year revenue to compare
Cash$188.9M
Total assets$294.9M
P/E (computed)Net income was not positive
P/S (computed)26.7×

Warning signs

Cash runway
6.2 months
$52.7M cash at September 30, 2026
Share count, 1 year
+28.2%
2025-10-31 to 2026-10-30
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$7.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$52.7M cash; operating cash flow -$25.6M a quarter.Report 2026-09-30
Shares outstanding45,958,509 (2026-10-30); 35,855,037 a year earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-01-22
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, San Francisco, California, United StatesPCAOB Form AP 2026-04-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $7.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$298K-$33.5M-$31.0M$52.7M$0$8.6M10-Q 2026-11-05
Q2 2026
2026-06-30
$2.5M-$26.1M-$19.3M$74.0M$0$10.4M10-Q 2026-08-05
Q1 2026
2026-03-31
$2.8M-$22.3M-$24.0M$241.8M$1.2M$10.3M10-Q 2026-05-08
Q4 2025
2025-12-31
$3.1M-$25.9M-$28.3M$188.9M$2.6M$9.0M10-K 2026-03-24
Q3 2025
2025-09-30
$2.1M-$20.2M-$16.0M$215.6M$4.1M$5.9M10-Q 2026-11-05
Q2 2025
2025-06-30
$2.4M-$21.6M-$20.0M$220.3M$5.6M$3.9M10-Q 2026-08-05
Q1 2025
2025-03-31
$1.5M-$12.9M-$17.4M$257.5M$7.1M$1.5M10-Q 2026-05-08
Q4 2024
2024-12-31
$0-$21.1M-$5.1M$354.3M$8.5M$010-K 2026-03-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-03-24
Latest annual report10-K2026-03-24
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 158 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.9%
1 month-0.4%
3 months-46.8%
Year to date-58.0%
1 year-28.1%
From 52-week high-77.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
FTHFaeth Therapeutics Inc.$9.28-7.48%$239.8M
ARCTArcturus Therapeutics Holdings Inc.$8.31-0.60%$239.5M
RCKTRocket Pharmaceuticals Inc.$2.16-6.09%$241.2M
CAMPCAMP4 Therapeutics Corporation$3.86+1.58%$242.2M
LFCRLifecore Biomedical Inc.$6.42-0.08%$243.2M
AMRNAmarin Corporation plc$11.31-0.62%$233.4M
QTTBQ32 Bio Inc.$8.29-4.82%$248.1M
VNDAVanda Pharmaceuticals Inc.$3.81-4.51%$230.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier